Abstract
Hypertensive urgencies-emergencies are important and common events. They are defined as a severe elevation in BP, higher than 180/120 mmHg, associated or not with the evidence of new or worsening organ damage for emergencies and urgencies respectively. Anamnestic information, physical examination and instrumental evaluation determine the following management that could need oral (for urgencies) or intravenous (for emergencies) anti-hypertensives drugs. The choice of the specific drugs depend on the underlying causes of the crisis, patient’s demographics, cardiovascular risk and comorbidities. For emergencies a maximum BP reduction of 20–25% within the first hour and then to 160/110–100 over next 2–6 h, is considered appropriate with a further gradual decrease over the next 24–48 h to reach normal BP levels. In the case of hypertensive urgencies, a gradual lowering of BP over 24–48 h with an oral medication is the best approach and an aggressive BP lowering should be avoided. Subsequent management with particular attention on chronic BP values control is important as the right treatment of the acute phase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2017;71(19):e127–248.
Farias S, Peacock WF, Gonzalez M, Levy PD. Impact of initial blood pressure on antihypertensive response in patients with acute hypertension. Am J Emerg Med. 2014;32:833–6.
Katz JN, Gore JM, Amin A, et al. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) Registry. Am Heart J. 2009;158:599–606.
Vilela Martin JF, Higashiama É, Garcia E, Luizon MR, Cipullo JP. Hypertensive crisis profile. Prevalence and clinical presentation. Arq Bras Cardiol. 2004;83:125–36.
Zampaglione B, Pascale C, Marchisio M, Cavalo-Perin P. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension. 1996;27:144–7.
Karras DJ, Kruus LK, Cienki JJ, et al. Evaluation and treatment of patients with severely elevated blood pressure in academic emergency departments: a multicenter study. Ann Emerg Med. 2006;47:230–6.
Donald G, Vidt MD. Emergency room management of hypertensive urgencies and emergencies. J. Clin. Hypertens. 2000;3:158–64.
Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131:1949–62.
van den Born BJH, Beutler JJ, Gaillard CAJM, de Gooijer A, van den Meiracker AH, Kroon AA. Dutch guideline for the management of hypertensive crisis—2010 revision. Neth J Med. 2011;69:248–55.
Muiesan M, Salvetti M, Amadoro V, di Somma S, Perlini S, Semplicini A, Borghi C, Volpe M, Saba P, Cameli M, Ciccone M, Maiello M, Modesti P. An update on hypertensive emergencies and urgencies. J Cardiovasc Med. 2015;16:372–82.
Kaya A, Tatlisu MA, Kaplan Kaya T, et al. Sublingual vs. oral captopril in hypertensive crisis. J Emerg Med. 2016;50:108–15.
Tartaglino B. In: Edizioni Medico Scientifiche, editors. Farmaci e procedure in medicina d’urgenza. 2nd ed. 2007.
Cline DM. Tintinalli’s emergency medicine. In: American College of Emergency Medicine, editors. A comprehensive study guide, 8th ed. 2016.
Gemici K. A comparison of safety and efficacy of sublingual captopril with sublingual nifedipine in hypertensive crisis. Int J Angiol. 1999;8:147–9.
Moharamzad Y. Clinical efficacy of sublingual captopril in the treatmentofhypertensiveurgency. Singapore Med J. 2009;50:400–2.
Damasceno A, Ferreira B, Patel S, Sevene EPJ. Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis. J Hum Hypertens. 1997;11:471–6.
Grossman E, Messerli FH, Grodzicky T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies. JAMA. 1996;276(16):1328–31.
Donnelly R, Meredith PA, Miller SHK, Howie CA, Elliott HL. Pharmacodynarnic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther. 1993;54:303–10.
Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs. 2008;68:283–97.
Marx P, Reid D. Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol. 1979;8:233S–8S.
Olsen KS, Svendsen LB, Larsen FS, Paulson OB. Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth. 1995;75:51–4.
Hypertension IN in the T of PA. Intravenous nicardipine in the treatment of postoperative arterial hypertension. J Cardiothorac Vasc Anesth. 1997;11:160–4.
Nordlander M, Sjöquist PO, Ericsson HRL. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004;22:227–50.
Rodríguez G, Varon J. Clevidipine: a unique agent for the critical care practitioner. Crit Care Shock. 2006;9:37–41.
Kw K. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension. Ann Pharmacother. 2009;43:1258–65.
Rivera A, Montoya E, Varon J. IBPC-6536-intravenous-clevidipine-butyrate-for-the-management-of-blood. Integr Blood Press Control. 2010;3:105–11.
Tulman DB, Stawicki SPA, Papadimos TJ, Murphy CV, Bergese SD. Advances in management of acute hypertension: a concise review. Discov Med. 2012;13:375383.
Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107:1110–21.
Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105:918–25.
Singla N, Warltier DC, Gandhi SD, et al. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (escape-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008;107:59–67.
Pollack CV, Varon J, Garrison NA, et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53:329–38.
Murphy MB, Murray CSG. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548–57.
White WB, Radford MJ, Gonzalez FM, Weed SG, McCabe EJ, Katz AM. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol. 1988;11:1118–23.
Khot UN, Novaro GM, Popović ZB, Mills RM, Thomas JD, Tuzcu EM, Hammer D, Nissen SEFG. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756–63.
Kondo T, Brock MBH. Effect of intra-arterial sodium nitroprusside on intracranial pressure and cerebral autoregulation. Jpn Heart J. 1984;25:231–7.
Mann T, Cohn PF, Holman LB, Green LH, Markis JE, Phillips DA. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation. 1978;57:732–8.
Niknahad HOP. Involvement of nitric oxide in nitroprusside-induced hepatocyte cytotoxicity. Biochem Pharmacol. 1996;51:1031–9.
Pasch T, Schulz VHG. Nitroprusside-induced formation of cyanide and its detoxication with thiosulfate during deliberate hypotension. J Cardiovasc Pharmacol. 1983;5:77–85.
Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet. 1984;9:239–51.
Ludden TM, Shepherd AMM, McNay JL, Lin MS. Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther. 1980;28:736–42.
Buch J. Urapidil, a dual-acting antihypertensive agent: current usage considerations. Adv Ther. 2010;27:426–43.
Alijotas-Reig J, Bove-Farre I, De Cabo-Frances F, Angles-Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am J Emerg Med. 2001;19:130–3.
Grossman E, Ironi ANMF. Comparative tolerability profile of hypertensive crisis treatments. Drug Saf. 1998;19:99–122.
Vuylsteke A, Vincent JL, Payen D, et al. Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for studying the treatment of acute hypertension (Euro-STAT) registry. Crit Care. 2011;15:1–9.
Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. Am J Heal Pharm. 2009;66:1343–52.
Vlcek M, Bur A, Woisetschlger C, Herkner H, Laggner AN, Hirschl MM. Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertension. J Hypertens. 2008;26:657–62.
Gore JM, Peterson E, Amin A, et al. Predictors of 90-day readmission among patients with acute severe hypertension. The cross-sectional observational Studying the Treatment of Acute hyperTension (STAT) study. Am Heart J. 2010;160:3.
Afonso L, Bandaru H, Rathod A, Badheka A, Ali Kizilbash M, Zmily H, Jacobsen G, Chattahi J, Mohamad T, Koneru J, Flack JWD. Prevalence, determinants, and clinical significance of cardiac troponin-I elevation in individuals admitted for a hypertensive emergency. J Clin Hypertens. 2011;13:551–6.
Badheka A, Shenoy M, Rathod A, Tuliani T, Afonso L. Long-term mortality and role of troponin elevation in hypertensive emergencies. Am J Cardiol. 2012;109:600.
Szczech LA, Granger CB, Dasta JF, et al. Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation. 2010;121:2183–91.
Patel KK, Young L, Howell EH, et al. Characteristics and outcomes of patients presenting with hypertensive urgency in the office setting. JAMA Intern Med. 2016;176:981–8.
Levy PD, Mahn JJ, Miller J, et al. Blood pressure treatment and outcomes in hypertensive patients without acute target organ damage: a retrospective cohort. Am J Emerg Med. 2015;33:1219–24.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
All the authors declares that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
This article is part of the topical collection on Hypertension Urgencies & Emergencies.
Rights and permissions
About this article
Cite this article
Maloberti, A., Cassano, G., Capsoni, N. et al. Therapeutic Approach to Hypertension Urgencies and Emergencies in the Emergency Room. High Blood Press Cardiovasc Prev 25, 177–189 (2018). https://doi.org/10.1007/s40292-018-0261-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40292-018-0261-4